Alcon, the global leader in eye care dedicated to helping people see brilliantly, was selected as a Gold winner for its innovative and personalized iLUX^® MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the Nonsurgical Hospital Supplies and Equipment category during an event held on June 11 in New York City. Products were judged based on design and engineering innovation, function and user-related innovation, patient benefits, business benefits and overall benefit to the healthcare system. The iLUX^® MGD Treatment System treats the signs and symptoms of Meibomian Gland Dysfunction (MGD), a leading cause of dry eye.¹ Handheld and portable, the unique design of the iLUX^® Device with Smart Tip Patient Interface enables ECPs to directly target a patient’s blocked Meibomian glands through the application of light-based heat followed by compression under direct visualization. The device expands the company’s current dry eye treatment offerings and allows practitioners to tailor treatment to the needs of each dry eye patient in a matter of minutes.²

“We are proud of the team at Tear Film Innovations for developing such an intuitive and critical technology for modern eye care, and celebrate this recognition by the MDEA,” said Adam Szaronos, Head of Dry Eye Devices, Alcon. “With our recent acquisition of Tear Film Innovations, and the addition of the iLUX^® MGD Treatment System to the Alcon portfolio, we are excited to apply our industry-leading experience toward addressing the primary unmet need in this space – implementation. This is how we will help more of our physician customers bring impactful and differentiated technology to the nearly 30 million US patients suffering from MGD.”

The MDEAs are the medical technology industry’s premier design competition, recognizing cutting-edge products that are saving lives, improving patient healthcare and transforming med tech. The 2019 MDEA juror panel is comprised of a balance of practicing doctors, nurses and technicians alongside industrial designers, engineers, manufacturers and human factor experts.

Important Product Information

Indication: The iLUX^® device is indicated for the application of localized heat and pressure therapy in adult patients with chronic disease of the eyelids, including Meibomian Gland Dysfunction (MGD), also known as evaporative eye. Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the iLUX^® device.